SCHEMBL402939

SCHEMBL402939

Cc1ccc(-c2nocc2C(=O)O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
GAA P10253 3/20 0.46
KDM4E B2RXH2 3/20 0.46
HPGD P15428 2/20 0.46
MAPT P10636 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MCL1 Q07820 1/20 0.45
NPC1 O15118 3/20 0.41
KMT2A Q03164 3/20 0.41
RAB9A P51151 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
AKR1C2 P52895 1/20 0.41
AKR1C1 Q04828 1/20 0.41
POLB P06746 2/20 0.40
LMNA P02545 1/20 0.40
MEN1 O00255 2/20 0.39
IP6K1 Q92551 1/20 0.39
IP6K3 Q96PC2 1/20 0.39
IP6K2 Q9UHH9 1/20 0.39
HDAC1 Q13547 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4024790 0.84 ALDH1A1 (0.45) ALDH1A1KMT2ATDP1POLBMEN1
SCHEMBL27830585 0.83 RXRA (0.41) ALDH1A1GAAKDM4EHPGDMAPT
SCHEMBL1776666 0.83 MAPK13 (0.49) KDM4ENPC1KMT2ARAB9ALMNA
SCHEMBL4022249 0.83 TPMT (0.39) KDM4EKMT2ATDP1POLB
SCHEMBL2929499 0.83 CDH1 (0.46) ALDH1A1GAAKDM4ESMN1; SMN2NPC1
SCHEMBL27934992 0.82 PTGS2 (0.43) ALDH1A1GAAKDM4EHPGDSMN1; SMN2
SCHEMBL8167740 0.82 RAB9A (0.49) ALDH1A1KDM4EMAPTSMN1; SMN2MCL1
SCHEMBL3545442 0.82 ALDH1A1 (0.52) ALDH1A1GAAKDM4EHPGDMAPT
SCHEMBL4022319 0.82 ALDH1A1 (0.52) ALDH1A1KDM4EHPGDMAPTSMN1; SMN2
SCHEMBL20241342 0.81 GABRA1 (0.40) GAAKDM4ENPC1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116887827-A Compounds and methods for modulating FXR 拓臻制药公司 2023-10-13 CN disclosed
US-20130041000-A1 NOVEL AZOLE COMPOUND AJINOMOTO CO., INC. (JP) 2013-02-14 US disclosed
US-20120022043-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH, INC. (US) 2012-01-26 US disclosed
EP-2348860-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS Genentech, Inc. (US) 2011-08-03 EP disclosed
WO-2010051549-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH, INC. (US) 2010-05-06 WO disclosed
US-7666888-B2 Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 AMGEN INC. (US) 2010-02-23 US disclosed
US-20090170911-A1 NOVEL AZOLE COMPOUND AJINOMOTO CO. INC (JP) 2009-07-02 US disclosed
EP-2051977-A2 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1 Amgen Inc. (US) 2009-04-29 EP disclosed
US-7517996-B2 Azole compound AJINOMOTO CO., INC. (JP) 2009-04-14 US disclosed
WO-2008011453-A2 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 AMGEN INC. (US) 2008-01-24 WO disclosed
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 AMGEN INC. 2008-01-24 US disclosed
US-20070054902-A1 Isoxazole derivatives as peroxisome proliferator-activated receptors agonists SHIONOGI & CO., LTD. (JP) 2007-03-08 US disclosed
US-20070054902-A1 Isoxazole derivatives as peroxisome proliferator-activated receptors agonists SHIONOGI & CO., LTD. (JP) 2007-03-08 US disclosed
US-20060194850-A1 Novel azole compound AJINOMOTO CO. INC (JP) 2006-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 HSD17B1, HSD11B1, HSD17B11 ALDH1A1 86/4885GAA 1712/4885KDM4E 702/4885
US-20090170911-A1 NOVEL AZOLE COMPOUND LPAR1, LPAR2, LPAR3 ALDH1A1 1467/4885GAA 3557/4885KDM4E 2822/4885
US-20120022043-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS JAK2, JAK1, JAK3 ALDH1A1 1236/4885GAA 3273/4885KDM4E 1299/4885
US-20130041000-A1 NOVEL AZOLE COMPOUND LPAR1, LPAR2, LPAR3 ALDH1A1 1467/4885GAA 3557/4885KDM4E 2822/4885
US-20060194850-A1 Novel azole compound LPAR1, LPAR2, LPAR3 ALDH1A1 1467/4885GAA 3557/4885KDM4E 2822/4885
US-20070054902-A1 Isoxazole derivatives as peroxisome proliferator-activated receptors agonists NR1H3, NR1H2, RXRA ALDH1A1 1698/4885GAA 4411/4885KDM4E 3202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.